MY123352A - Dofetilide polymorphs - Google Patents

Dofetilide polymorphs

Info

Publication number
MY123352A
MY123352A MYPI98004829A MYPI9804829A MY123352A MY 123352 A MY123352 A MY 123352A MY PI98004829 A MYPI98004829 A MY PI98004829A MY PI9804829 A MYPI9804829 A MY PI9804829A MY 123352 A MY123352 A MY 123352A
Authority
MY
Malaysia
Prior art keywords
polymorphs
dofetilide
substantially pure
relates
dofetilide polymorphs
Prior art date
Application number
MYPI98004829A
Inventor
Ian Colin Appleby
Trevor Jack Newbury
Gary Nichols
Original Assignee
Pfizer Res & Dev Company N V S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10821150&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY123352(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Res & Dev Company N V S A filed Critical Pfizer Res & Dev Company N V S A
Publication of MY123352A publication Critical patent/MY123352A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

THIS INVENTION RELATES TO A SUBSTANTIALLY PURE,CRYSTALLINE DOFETILIDE POLYMORPH P162 WHICH IS CHARACTERIZED BY THE FOLLOWING:DIFFERENTIAL SCANNING CALORIMETRY (DSC) IN WHICH IT EXHIBITS AN ENDOTHERMIC THERMAL EVENT AT THE ABOUT 162°C; POWDER X-RAY DIFFRACTION PATTERN (PXRD) WITH MAIN PEAK WITH INTERPLANAR SPACINGS AT DA21.303,10.597,7.053,5.288,4.856,4.793,4.569,4.504,4.430,4.256,4.230,4.133,3.956,3.611,3.866,3.674,3.606,3.524,3.424,3.384,3.309,3.255,3.171,3.083,3.038,3.021,2.893,2.842,2.776,2.679,2.598,2.557,2.503,2.482,2.436,2.419,2.399,2.345 AND 2.323; AND AN INFRARED (IR) SPECTRUM AS A MULL IN NUJOL WHICH SHOWS ABSORPTION BANDS AT 3246,3013,2807,2776,1907,1611,1593,1510,1398,1366,1357,1321,1300,1277,1251,1220,1171,1146,1106,1091,1051,1031,1023,994,966,934,925,903,851,825,808,774,723,657,603,586,559,538,528,509,499,461 AND 431CM-1. ALSO INCLUDED IN THIS INVENTION ARE DOFETILIDE POLYMORPHS P162A AND P143.THIS INVENTION FURTHER RELATES TO PROCESSES FOR THE PREPARATION OF POLYMORPHS P162,P162A,P143,IN ADDITION TO PHARMACEUTICAL COMPOSITIONS CONTAINING THESE POLYMORPHS.THIS INVENTION ADDITIONALLY RELATES TO METHODS OF TREATING HEART FAILURE AND CARDIAC ARRHYTHMIA USING SUBSTANTIALLY PURE DOFETILIDE POLYMORPHS P162,P162A OR P143.
MYPI98004829A 1997-10-27 1998-10-23 Dofetilide polymorphs MY123352A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9722662.5A GB9722662D0 (en) 1997-10-27 1997-10-27 Polymorphs

Publications (1)

Publication Number Publication Date
MY123352A true MY123352A (en) 2006-05-31

Family

ID=10821150

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI98004829A MY123352A (en) 1997-10-27 1998-10-23 Dofetilide polymorphs

Country Status (46)

Country Link
US (1) US6124363A (en)
EP (1) EP1027329B1 (en)
JP (1) JP3569495B2 (en)
KR (1) KR100366167B1 (en)
CN (1) CN1146537C (en)
AP (1) AP906A (en)
AR (1) AR015193A1 (en)
AT (1) ATE232199T1 (en)
AU (1) AU737668B2 (en)
BG (1) BG64125B1 (en)
BR (1) BR9813308A (en)
CA (1) CA2307121C (en)
CO (1) CO4970768A1 (en)
DE (1) DE69811256T2 (en)
DK (1) DK1027329T3 (en)
DZ (1) DZ2632A1 (en)
EA (1) EA002656B1 (en)
ES (1) ES2190620T3 (en)
GB (1) GB9722662D0 (en)
GT (1) GT199800165A (en)
HN (1) HN1998000165A (en)
HR (1) HRP20000247B1 (en)
HU (1) HUP0004735A3 (en)
ID (1) ID24658A (en)
IL (1) IL135435A0 (en)
IS (1) IS2179B (en)
MA (1) MA24683A1 (en)
MY (1) MY123352A (en)
NO (1) NO325630B1 (en)
NZ (1) NZ503785A (en)
OA (1) OA11350A (en)
PA (1) PA8462001A1 (en)
PE (1) PE122199A1 (en)
PL (1) PL197379B1 (en)
PT (1) PT1027329E (en)
SA (1) SA98190834B1 (en)
SI (1) SI1027329T1 (en)
SK (1) SK5862000A3 (en)
TN (1) TNSN98193A1 (en)
TR (1) TR200001135T2 (en)
TW (1) TW449589B (en)
UA (1) UA67755C2 (en)
UY (2) UY25222A1 (en)
WO (1) WO1999021829A1 (en)
YU (1) YU24000A (en)
ZA (1) ZA989719B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10019067C1 (en) * 2000-04-18 2001-10-04 Lohmann Therapie Syst Lts Transdermal plaster comprising dofetilide, is useful for treatment of cardiovascular disorders
US7326772B2 (en) * 2005-05-12 2008-02-05 Penta Biotech, Inc. Peptide for assaying hERG channel binding
CZ2017772A3 (en) 2017-12-01 2019-05-29 Farmak, A.S. Method of preparing N- [4- (2 - {[2- (4-methanesulfonamidophenoxy) ethyl] (methyl) amino} ethyl) phenyl] methanesulfonamide (Dofetilide)
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US12396970B2 (en) 2021-08-20 2025-08-26 AltaThera Pharmaceuticals LLC Anti-arrhythmic compositions and methods
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG18188A (en) * 1986-05-01 1992-09-30 Pfizer Ltd Process for preparation anti-arhythmia agents
EP0898964A1 (en) * 1997-08-19 1999-03-03 Pfizer Inc. Method for treating heart failure

Also Published As

Publication number Publication date
PA8462001A1 (en) 2000-05-24
CO4970768A1 (en) 2000-11-07
PL197379B1 (en) 2008-03-31
DZ2632A1 (en) 2003-03-08
UA67755C2 (en) 2004-07-15
AU737668B2 (en) 2001-08-30
HUP0004735A3 (en) 2001-12-28
DK1027329T3 (en) 2003-02-24
EA200000365A1 (en) 2000-12-25
NO325630B1 (en) 2008-06-30
UY25222A1 (en) 2000-12-29
ZA989719B (en) 2000-04-26
US6124363A (en) 2000-09-26
ID24658A (en) 2000-07-27
NO20002191D0 (en) 2000-04-27
IL135435A0 (en) 2001-05-20
YU24000A (en) 2003-02-28
SK5862000A3 (en) 2001-10-08
HN1998000165A (en) 1999-02-09
TNSN98193A1 (en) 2005-03-15
NZ503785A (en) 2004-11-26
AP9801371A0 (en) 1998-12-31
EA002656B1 (en) 2002-08-29
JP3569495B2 (en) 2004-09-22
WO1999021829A1 (en) 1999-05-06
MA24683A1 (en) 1999-07-01
UY25341A1 (en) 1999-09-27
ES2190620T3 (en) 2003-08-01
KR100366167B1 (en) 2003-01-09
BR9813308A (en) 2000-08-22
GT199800165A (en) 2000-04-19
AP906A (en) 2000-11-30
GB9722662D0 (en) 1997-12-24
CN1278246A (en) 2000-12-27
CA2307121A1 (en) 1999-05-06
TR200001135T2 (en) 2000-09-21
NO20002191L (en) 2000-04-27
IS5426A (en) 2000-03-31
PE122199A1 (en) 1999-12-02
ATE232199T1 (en) 2003-02-15
AR015193A1 (en) 2001-04-18
HRP20000247A2 (en) 2000-10-31
OA11350A (en) 2003-12-17
SI1027329T1 (en) 2003-04-30
HK1033933A1 (en) 2001-10-05
JP2001521023A (en) 2001-11-06
SA98190834B1 (en) 2006-08-21
KR20010031439A (en) 2001-04-16
DE69811256T2 (en) 2003-09-18
EP1027329A1 (en) 2000-08-16
CA2307121C (en) 2006-12-05
TW449589B (en) 2001-08-11
HRP20000247B1 (en) 2002-08-31
EP1027329B1 (en) 2003-02-05
BG64125B1 (en) 2004-01-30
CN1146537C (en) 2004-04-21
AU2151299A (en) 1999-05-17
PL340805A1 (en) 2001-02-26
BG104373A (en) 2000-12-29
HUP0004735A2 (en) 2001-10-28
PT1027329E (en) 2003-04-30
DE69811256D1 (en) 2003-03-13
IS2179B (en) 2006-12-15

Similar Documents

Publication Publication Date Title
AU712922B2 (en) Crystalline hydrochloride of (R)-(-)-2-N-(4- (1,1-dioxido-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl)- aminomethyl-chroman
GR3020139T3 (en) Dermorphin analogs, their methods of preparation, pharmaceutical compositions, and methods of therapeutic treatment using the same
EP2744811A1 (en) Inhibitors of human immunodeficiency virus replication
MY123352A (en) Dofetilide polymorphs
HUT37768A (en) Process for preparing benzoxa-zepines and pharmaceutical compositions containing such compounds
ZA898273B (en) Process for the preparation of 3,5-dimethyl-4-methoxy-pyridine derivatives and novel intermediate for said preparation
NZ567030A (en) Quaternary alpha-aminocarboxamide derivatives as modulators of voltage-gated sodium channels
HUT36127A (en) Process for preparing new pyrrolo-benzoxazepines
HUT48616A (en) Process for producing thienylethylamine derivatives
Schreiber et al. Diastereotopic selectivity at prochiral carbon centers. A stereodivergent synthesis of the talaromycins.
GEP20043365B (en) Polymorphic Salt
IE800477L (en) Pyrimidine derivatives
AU2176197A (en) 3,4-disubstituted phenylethanolaminotetralincarboxylate derivatives
PL309664A1 (en) Derivatives ofbenzoilecgonine, ecgonine and ecgonidine as pharmaceutic agents
IL82564A0 (en) Synergistin derivatives,their preparation and pharmaceutical compositions which contain them
Remy et al. (+)-and (-)-3-Methoxycyproheptadine. A comparative evaluation of the antiserotonin, antihistaminic, anticholinergic, and orexigenic properties with cyproheptadine
PT95526A (en) PROCESS FOR THE PREPARATION OF DERIVATIVES OF 10,5- (IMINOMETHANE) -5H-DIBENZO (A, D) CYCLOHEPTENE USES AS NEUROPROTECTING AGENTS
CA2225022A1 (en) New polymorphous form of doxazosine mesylate (form iii)
GR3034605T3 (en) Amorphous piretanide, piretanide polymorphs, process for their preparation and their use
DE69736924D1 (en) Phenylethanolaminotetralincarboxamid-derivate
JP2828548B2 (en) Novel 2-piperidinecarboxylic acid derivative
HU199474B (en) Process for producing new imidazo/1,2-a/pyrimidines and pharmaceutical compositions comprising these compounds as active ingredient
MX9700792A (en) Novel polymorphs of lesopitron dichlorohydrate and its hydrated forms, preparation methods and compositions containing them.
DE68910932T2 (en) 17-thia-20,21-dinoreburnameninderivate, processes and intermediates for their preparation, their use as medicines and pharmaceutical preparations containing them.
Brocherieux-Lanoy et al. Lewis acid mediated diastereoselective allylation of 3-menthyloxycarbonyl-5, 6-dihydropyridin-4-ones